Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
WARREN, N.J., Sept. 07, 2017 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference, and the Ladenburg Thalmann 3rd Annual Healthcare Conference.
| Rodman & Renshaw 19th Annual Global Investment Conference | |
| Date: | Tuesday, September 12 |
| Time: | 9:35 am Eastern Time |
| Location: | The Lotte New York Palace Hotel, Kennedy I Ballroom |
| Webcast: | http://wsw.com/webcast/rrshq27/blph |
| Ladenburg Thalmann 3rd Annual Healthcare Conference | |
| Date: | Tuesday, September 26 |
| Time: | 1:30 pm Eastern Time |
| Location: | Sofitel Hotel, New York City, Orleans Ballroom |
| Webcast: | http://wsw.com/webcast/ladenburg3/blph |
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of pulmonary arterial hypertension (PAH), for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contact Bellerophon Therapeutics: Fabian Tenenbaum, Chief Executive Officer (908) 574-4819 LifeSci Advisors Bob Yedid, Managing Director (646) 597-6989 [email protected]
